Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

West, Howard; McCleod, Michael; Hussein, Maen; Morabito, Alessandro; Rittmeyer, Achim; Conter, Henry Jacob; Kopp, Hans‐Georg; Daniel, Davey B.; McCune, Steven L.; Mekhail, Tarek; Zer, Alona; Reinmuth, Niels; Sadiq, Ahad A.; Sandler, Alan; Lin, Weihong; Lohmann, Tania Ochi; Archer, Venice; Wang, Lijia; Kowanetz, Marcin; Cappuzzo, Federico

doi:10.1016/s1470-2045(19)30167-6

Cited by 1,299 publications

(1,199 citation statements)

References 21 publications

Supporting

Mentioning

1,064

Contrasting

Unclassified

Order By: Relevance

“…A total of 3,691 related studies were identified by the initial search strategy ( Figure S1). Finally, 20 randomized controlled trails with 22 studies involving 12,025 patients were included for the quantitative analysis (Barlesi et al, 2018;Borghaei et al, 2015;Borghaei et al, 2018;Brahmer et al, 2015;Carbone et al, 2017;Fehrenbacher et al, 2016;Gandhi et al, 2018;Govindan et al, 2017;Hellmann et al, 2018;Herbst et al, 2016;Jotte et al, 2018;Langer et al, 2016;Lynch et al, 2012;Mok et al, 2019;Papadimitrakopoulou et al, 2018;Paz-Ares et al, 2018;Reck et al, 2016;Rittmeyer et al, 2017;Socinski et al, 2018;West et al, 2019;Wu et al, 2019). Half of these 22 studies investigated the efficacy of ICI monotherapy versus chemotherapy, including 1 study about avelumab, 2 about ATE, 4 about NIV, and 4 about PEM.…”

Section: Literature Searchmentioning

confidence: 99%

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

Wang

Qiao

Jiang

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Background: Lung cancer is the leading cause of cancer-related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non-small-cell lung cancer (NSCLC), but it remains unanswered which is superior. The current study aimed to estimate the comparative efficacy and safety of ICI-chemotherapy versus ICI-monotherapy in advanced NSCLC.Methods: Studies were identified by searching PubMed, Embase, and Cochrane library. The randomized controlled trials (RCTs) that ICI monotherapy or ICI plus chemotherapy compared with chemotherapy in NSCLC were included with available primary endpoints of progression-free survival (PFS), overall survival (OS), objective response rate, or treatment-related adverse events. A fixed-effect or random-effects model was adopted depending on between-study heterogeneity.Results: A total of 20 RCTs involving 12,025 patients with NSCLC were included. Both ICI-monotherapy and ICI-chemotherapy resulted in significantly prolonged survival compared to chemotherapy and the former led to significantly longer PFS. The magnitude of survival benefits appeared to be greatest among those treated with pembrolizumab plus platinum-based chemotherapy (OS, 0.56; PFS, 0.54). Additionally, OS and PFS advantages of ICI therapies were observed in patients with NSCLC with low or high programmed cell death 1 ligand 1 (PD-L1) expression level, but not in intermediate PD-L1 TPS.Conclusions: Pembrolizumab plus platinum-based chemotherapy was recommended as the optimal first-line therapy for advanced patients with NSCLC.

show abstract

Section: Literature Searchmentioning

confidence: 99%

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

Wang

Qiao

Jiang

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…IMpower-150 and IMpower-130 evaluated atezolizumab plus chemotherapy, with or without bevacizumab, but both trials failed to meet their OS end points. 12,16 Data from these trials do not support the use of atezolizumabbased chemoimmunotherapy in the treatment of EGFR + or ALK + aNSCLC. Two ongoing trials, KEYNOTE-789 (NCT03515837), evaluating pembrolizumab-based chemoimmunotherapy, and CheckMate-722 (NCT02864251), evaluating nivolumab-based chemoimmunotherapy, are ongoing, and final results from these studies are expected in 2023 and 2025, respectively.…”

Section: Anaplastic Lymphoma Kinase/epidermal Growth Factor Receptormentioning

confidence: 99%

“…Several studies have investigated the safety and efficacy of ICIs in patients with EGFR+/ALK + metastatic NSCLC who have progressed on TKI therapy. IMpower‐150 and IMpower‐130 evaluated atezolizumab plus chemotherapy, with or without bevacizumab, but both trials failed to meet their OS end points . Data from these trials do not support the use of atezolizumab‐based chemoimmunotherapy in the treatment of EGFR + or ALK + aNSCLC.…”

Section: Patient Selectionmentioning

confidence: 99%

“…The pivotal clinical trials for these treatments have been reviewed in depth, and results are summarized in Table . This review focuses on patient and treatment selection strategies to optimize clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

“…7 Nivolumab (anti-PD-1) is also under investigation in combination with chemotherapy as first-line therapy, and interim PFS results favor chemoimmunotherapy over chemotherapy in patients with high tumor mutational burden (10 or more mutations/megabase [mut/Mb]) and PD-L1 less than 1%, although the OS end point for PD-L1-unselected nonsquamous NSCLC was not met. 8,9 The pivotal clinical trials for these treatments have been reviewed in depth, [3][4][5][6][8][9][10][11][12][13][14] and results are summarized in Table 1. This review focuses on patient and treatment selection strategies to optimize clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer

La‐Beck

Nguyen

et al. 2020

Pharmacotherapy

View full text Add to dashboard Cite

The rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) now includes two agents, pembrolizumab and atezolizumab, approved for first‐line treatment of advanced non–small cell lung cancer (aNSCLC) as monotherapy or as part of chemoimmunotherapy. This review summarizes the clinical evidence supporting these indications, with a focus on strategies to optimize patient outcomes. These strategies include patient and tumor factors, adverse‐effect profiles, pharmacokinetic and pharmacodynamic drug interactions, and quality of life and cost‐effectiveness considerations. We performed a systematic literature search of the PubMed, Scopus, and Google Scholar databases, as well as a search of the conference proceedings of the American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research (through August 31, 2019). The addition of ICIs to conventional chemotherapy as first‐line treatment against aNSCLC is now part of the standard of care options. However, even though ICIs may be cost‐effective in patients with aNSCLC, high drug and other associated costs can still be a barrier to treatment for patients. Moreover, the adverse‐effect profiles of ICIs differ significantly from conventional chemotherapy, and some immune‐related adverse effects may have a lasting impact on quality of life. Therefore, in adhering to a patient‐centered model of care, clinicians should be mindful of patient‐ and treatment‐specific factors when considering therapeutic options for patients with aNSCLC. Although the role of the immune system in cancer progression and regression has not been fully elucidated, the full clinical potential of immunotherapeutics in the treatment of cancer likely remains to be unleashed.

show abstract

Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Sex, age, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) may affect immune response. However, the association of these factors with the survival benefit of cancer immunotherapy with immune checkpoint inhibitors (ICIs) remains unclear. OBJECTIVE To assess the potential sex, age, and ECOG PS differences of immunotherapy survival benefit in patients with advanced cancer.

show abstract

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Cited by 1,299 publications

References 21 publications

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer

Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials

Contact Info

Product

Resources

About